)
Gilead Sciences (GILD) investor relations material
Gilead Sciences Evercore ISI 8th Annual HealthCONx Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.R&D strategy and portfolio updates
Focus remains on virology, oncology, and inflammation, with strong performance and multiple launches in the past year.
HIV prevention and treatment portfolio is expanding, with new long-acting injectable and oral regimens under development.
Portfolio prioritization led to advancement of GS-3242, a long-acting integrase inhibitor, over similar candidates.
Ongoing studies include Purpose 365 for annual HIV prevention and Artistry trials for new HIV regimens.
Inflammation pipeline includes oral alpha-4 beta-7 in phase II for IBD, with potential for combination therapies.
HIV pipeline and clinical trial insights
Intramuscular HIV prevention options are being studied for both annual and six-month dosing, with decisions pending data.
High patient retention and compliance observed in clinical trials for long-acting injectables, with minimal issues from injection site nodules.
GS-3242 is prioritized for long-acting treatment, while Biktarvy remains standard of care for naive patients.
Combination regimens are being developed to address resistance, with encouraging data on low resistance formation.
BIC-Len regimen is positioned for switch settings, with ongoing studies in both complex and general switch populations.
Inflammation and metabolic pipeline
Oral GLP-1 candidate is in phase I, with future development or partnership decisions pending data.
Oral alpha-4 beta-7 for IBD is a strategic focus, with phase II data expected soon and potential for use in various disease stages.
Internal combination partners for IBD include TPL2 and FXR agonists, with external partnerships also considered.
RA pipeline includes a PD-1 agonist in clinical trials.
Next Gilead Sciences earnings date
Next Gilead Sciences earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage